



Method Development and Validation for The Estimation of Zafirlukast in Bulk and Marketed Tablet Formulation by Using RP-HPLC Method

Alvia Anjum*, Kiran, Vijaysharma, Supriya, Vaishnavi, Bhavani

Moonray Institute of Pharmaceutical Science, Raikal, Shadnagar, Rangareddy, Telangana

Received: 12 Mar 2025 / Accepted: 7 Apr 2025 / Published online: 1 Jul 2025

*Corresponding Author Email: alviaanjum123@gmail.com

Abstract

A simple, rapid, specific and accurate reverse phase high performance liquid chromatographic method has been developed for the validated of Zafirlukast in bulk as well as in marketed pharmaceutical dosage form. This separation was performed on a Symmetry ODS C₁₈ (4.6mm×250mm, 5µm) column with Methanol: Phosphate Buffer (40:60%) v/v as mobile phase at a flow rate of 1.0 mL min⁻¹ with UV detection at 235 nm; the constant column temperature was Ambient. The run time under these chromatographic conditions was less than 8 min. The retention time of Zafirlukast was found to be 2.293min. The calibration plot was linear over the concentration range of 6–14 µg mL⁻¹ with limits of detection and quantification values of 1.2 and 3.6 ng mL⁻¹ respectively. The mean % assay of marketed formulation was found to be 99.86%, and % recovery was observed in the range of 98-102%. Relative standard deviation for the precision study was found <2%. The developed method is simple, precise, specific, accurate and rapid, making it suitable for estimation of Zafirlukast in bulk and marketed pharmaceutical dosage form dosage form.

Keywords

Zafirlukast, RP-HPLC, Validation, Accuracy, Precision, ICH Guidelines.

INTRODUCTION

Zafirlukast is a tolyl compound and leukotriene receptor antagonist (LTRA), with anti-asthmatic and potential capsular contracture-preventing activities. Upon administration, Zafirlukast selectively and competitively binds to and blocks the cysteinyl leukotriene 1 receptor (CYSLTR1), thereby preventing the potent pro-inflammatory mediator's leukotriene C₄, D₄ and E₄ from binding¹. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability

and bronchoconstriction. In addition, Zafirlukast may decrease collagen deposition, fibrosis, and capsular thickness after implantation, thereby preventing scar tissue. For the prophylaxis and chronic treatment of asthma². Zafirlukast is used to prevent asthma symptoms. Zafirlukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of certain natural substances that cause swelling and tightening of the airways³. The IUPAC Name of Zafirlukast is cyclopentyl N-[3-[[2-methoxy-4-[(2-methyl phenyl) sulfonyl carbamoyl] phenyl] methyl]-1-methyl indol-5-yl] carbamate. The Chemical Structure of Zafirlukast is as follows




Fig1: Chemical Structure of Zafirlukast

MATERIALS AND METHODS

Instruments Used

Table 1: Instruments used

Instruments and Glass wares	Model
HPLC	WATERS Alliance 2695 separation module, Software: Empower 2, 996 PDA detector.
pH meter	Lab India
Weighing machine	Sartorius
Volumetric flasks	Borosil
Pipettes and Burettes	Borosil
Beakers	Borosil
Digital ultra sonicator	Labman

Chemicals Used:

Table 2: Chemicals used

Chemical	Brand Names
Zafirlukast	Synpharma Lab, Dilsuknagar
Water and Methanol for HPLC	LICHROSOLV (MERCK)
Acetonitrile for HPLC	Merck

HPLC Method Development:

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate⁴ to dissolve and removal of air completely and make volume up to the mark with the same Methanol. Further pipette 0.1ml of the above Zafirlukast stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines²⁷.

Mobile Phase Optimization:

Initially the mobile phase tried was Methanol and Methanol: Water with varying proportions. Finally, the mobile phase was optimized to Methanol: Phosphate Buffer in proportion 40:60% v/v.

Optimization of Column:

The method was performed with various C18 columns like, X- bridge column, Xterra, and C18 column. Symmetry ODS C₁₈ (4.6mm x 250mm, 5μm) was found to be ideal as it gave good peak shape and resolution at 1.0ml/min flow⁵.

Preparation of Buffer and Mobile Phase:

Preparation of Potassium dihydrogen Phosphate (KH₂PO₄) buffer (pH-3.4):

Dissolve 6.8043 of potassium dihydrogen phosphate in 1000 ml HPLC water and adjust the pH 3.4 with diluted orthophosphoric acid. Filter and sonicate the solution by vacuum filtration and ultra-sonication⁶.

Preparation of Mobile Phase:

Accurately measured 400 ml (40%) of Methanol, 600 ml of Phosphate buffer (60%) were mixed and degassed in digital ultra sonicator for 15 minutes and then filtered through 0.45 μ filter under vacuum filtration⁷.

Diluent Preparation:

The Mobile phase was used as the diluent⁸.

Method Validation Parameters

System Suitability

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution) Further pipette 0.1ml of the above Zafirlukast stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

Procedure:

The standard solution was injected for five times and measured the area for all five injections in HPLC. The

%RSD for the area of five replicate injections was found to be within the specified limits.

Specificity:

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flask add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.1ml of the above Zafirlukast stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

Preparation of Sample Solution:

%ASSAY =

$$\frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

Linearity and Range:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flask add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Preparation of Level – I (6ppm of Zafirlukast):

Take 0.6ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – II (8ppm of Zafirlukast):

Take 0.8ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – III (10ppm of Zafirlukast):

Take 0.1ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator¹¹.

Preparation of Level – IV (12ppm of Zafirlukast):

Take 0.12ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Preparation of Level – V (14ppm of Zafirlukast):

Take 0.14ml of stock solution in to 10ml of volumetric flask and make up the volume up to mark with diluents and sonicate the solution for bubble entrapment using ultrasonicator.

Procedure:

Inject each level into the chromatographic system¹² and measure the peak area.

Plot a graph of peak area versus concentration (on X-axis concentration and on Y-axis Peak area) and calculate the correlation coefficient.

Weight 10 mg equivalent weight of Zafirlukast sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Further pipette 0.1ml of Zafirlukast above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

Procedure:

Inject the three replicate injections of standard and sample solutions and calculate the assay^{9,10} by using formula:

Precision

Repeatability

Preparation of Zafirlukast Product Solution for Precision:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flask add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.1ml of the above Zafirlukast stock solutions into a 10ml volumetric flask and dilute up to the mark with diluents.

Procedure:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Intermediate Precision:

To evaluate the intermediate precision (also known as Ruggedness) of the method, Precision was performed on different days by maintaining same conditions.

Procedure:

Analyst 1:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Analyst 2:

The standard solution was injected for six times and measured the area for all six injections in HPLC. The %RSD for the area of six replicate injections was found to be within the specified limits.

Accuracy:

For Preparation of 50% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric

flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.05ml of the above Zafirlukast stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

For Preparation of 100% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.1ml of the above Zafirlukast stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

For Preparation of 150% Standard Stock Solution:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.15ml of the above Zafirlukast stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

Procedure:

Inject the Three replicate injections of individual concentrations (50%, 100%, 150%) were made under the optimized conditions. Recorded the chromatograms and measured the peak responses.

Calculate the Amount found and Amount added for Zafirlukast and calculate the individual recovery and mean recovery values.

Robustness:

The analysis was performed in different conditions to find the variability of test results. The following conditions are checked for variation of results. .

For Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Zafirlukast working standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 0.1ml of the above Zafirlukast stock solution into a 10ml volumetric flask and dilute up to the mark with diluents.

Effect of Variation of Flow Conditions:

The sample was analyzed at 0.9 ml/min and 1.1 ml/min instead of 1ml/min, remaining conditions are same. 10 μ l of the above sample was injected and chromatograms were recorded.

Effect of Variation of Mobile Phase Organic Composition:

The sample was analyzed by variation of mobile phase i.e. Methanol: Phosphate Buffer was taken in the ratio and 45:55, 35:65 instead (40:60), remaining conditions are same. 20 μ l of the above sample was injected and chromatograms were recorded.

RESULTS AND DISCUSSION

Method Development:

Optimized Chromatographic Conditions

Mobile phase ratio	: Methanol: Phosphate Buffer (40:60%) v/v
Column	: Symmetry ODS C18 (4.6mm $\times$ 250mm, 5 μ m)
Column temperature	: Ambient
Wavelength	: 235nm
Flow rate	: 1.0ml/min
Injection volume	: 10 μ l
Run time	: 8.0min




Fig 2: Optimized Chromatographic Condition

Method Validation:

The method¹³ was validated by following the ICH and USP guidelines for system suitability, linearity,

accuracy, precision, specificity and limit of detection (LOD).

System Suitability:

The system suitability¹⁴ was checked by analyzing the repeatability of retention time, tailing factor and theoretical plates of the column.

Table 3: Results of System Suitability for Zafirlukast

S.No.	Peak Name	RT	Area (μV*sec)	Height (μV)	USP Plate Count	USP Tailing
1	Zafirlukast	2.277	1652847	185647	6589	1.24
2	Zafirlukast	2.277	1653658	186254	6587	1.26
3	Zafirlukast	2.267	1654521	185475	6584	1.28
4	Zafirlukast	2.265	1653564	186594	6582	1.29
5	Zafirlukast	2.277	1658745		6895	1.24
Mean			1654667			
Std. Dev.			2355.764			
% RSD			0.142371			

Specificity

The ICH documents define specificity¹⁵ as the ability to assess unequivocally the analyte in the presence of components that may be expected to be present,

such as impurities, degradation products, and matrix components.

Analytical method was tested for specificity to measure accurately quantities Zafirlukast in drug product.

%ASSAY =

$$\frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

= 99.40%

The % purity¹⁶ of Zafirlukast in pharmaceutical dosage form was found to be 99.40%.

Linearity

To evaluate the linearity¹⁷ of this method, five standard solutions covering the range of 6 to 14 μg/ml were analyzed using the method. The plot

of peak area ratio of drug and against respective concentration of the drug was found to be linear in the range as shown in figure -3. The regression equation¹⁸ was found to be $Y = 185008X - 16179$ and the coefficient of determination R^2 of the standard curve was found to be 0.9996.

Chromatographic Data for Linearity Study:

Table 4: Data for Linearity of Zafirlukast

Concentration μg/ml	Average Peak Area
6	1078475
8	1461129
10	1808358
12	2211573
14	2593778




Fig 3: Linearity Curve of Zafirlukast

Linearity Plot: The plot of Concentration (x) versus the Average Peak Area (y) data of Zafirlukast is a straight line.

$$Y = mx + c$$

Slope (m) = 18500

Intercept (c) = 16179

Correlation Coefficient (r) = 0.999

Validation Criteria: The response linearity is verified if the Correlation Coefficient¹⁹ is 0.99 or greater.

Conclusion: Correlation Coefficient (r) is 0.99, and the intercept is 0.16179. These values meet the validation criteria.

Precision:

The precision²⁰ of an analytical procedure expresses the closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions²¹.

Repeatability: Obtained Six (6) replicates of 100% accuracy solution as per experimental conditions. Recorded the peak areas and calculated % RSD²².

Table 5: Results of Repeatability for Zafirlukast:

S. No.	Peak Name	Retention time	Area (μV*sec)	Height (μV)	USP Plate Count	USP Tailing
1	Zafirlukast	2.293	1658954	186958	1.26	6785
2	Zafirlukast	2.276	1658745	187548	1.27	6854
3	Zafirlukast	2.286	1659865	189854	1.26	6852
4	Zafirlukast	2.277	1653254	186985	1.25	6784
5	Zafirlukast	2.280	1654781	189542	1.24	6895
6	Zafirlukast	2.293	1661324	187586	1.28	6965
Mean			1657821			
Std. Dev			3120.433			
%RSD			0.188225			

Intermediate Precision:

Analyst-1:

Table 6: Results of Intermediate Precision for Zafirlukast

S.No.	Peak Name	RT	Area (μV*sec)	Height (μV)	USP Plate Count	USP Tailing
1	Zafirlukast	2.274	1678541	186589	6587	1.26
2	Zafirlukast	2.258	1685985	186598	6321	1.26
3	Zafirlukast	2.267	1685745	186985	6385	1.25
4	Zafirlukast	2.270	1685987	187854	6580	1.26
5	Zafirlukast	2.264	1698526	187549	6721	1.27
6	Zafirlukast	2.265	1685943	186598	6637	1.26
Mean			1686788			
Std. Dev.			6463.466			
% RSD			0.383182			

Analyst 2:

Table 7: Results of Intermediate precision Analyst 2 for Zafirlukast

S. No.	Peak Name	RT	Area (μV*sec)	Height (μV)	USP Plate count	USP Tailing
1	Zafirlukast	2.277	1665847	167481	6854	1.25
2	Zafirlukast	2.255	1658989	167854	6785	1.26
3	Zafirlukast	2.265	1659845	167895	6854	1.24
4	Zafirlukast	2.255	1665964	167854	6895	1.26
5	Zafirlukast	2.253	1659863	168585	6459	1.25
6	Zafirlukast	2.252	1665986	167859	6456	1.26
Mean			1662749			
Std. Dev.			3501.766			
% RSD			0.210601			

Accuracy: As per the ICH guideline, accuracy is inferred once linearity, specificity and precision of

the method are established. This approach was followed to establish the accuracy²³ of the method and the method was found to be accurate.

Table 8: The Accuracy Results for Zafirlukast

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	109068.3	5	5.021	100.420%	100.72%
100%	202187	10	10.054	100.540%	
150%	297032.3	15	15.181	101.206%	

Limit of Detection

The detection limit²⁴ of an individual analytical procedure is the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.

$$LOD = 3.3 \times \sigma / s$$

Where

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 0.95 µg/ml

Quantitation Limit

The quantitation limit²⁵ of an individual analytical procedure is the lowest amount of analyte in a sample which can be quantitatively determined.

no significant change in the parameters like resolution, tailing factor, asymmetric factor, and plate count.

$$LOQ = 10 \times \sigma / S$$

Where

σ = Standard deviation of the response

S = Slope of the calibration curve

Result:

= 2.9 µg/ml

Robustness:

The robustness²⁶ was performed for the flow rate variations from 0.9 ml/min to 1.1 ml/min and mobile phase ratio variation from more organic phase to less organic phase ratio for Zafirlukast. The method is robust only in less flow condition. The standard of Zafirlukast was injected by changing the conditions of chromatography. There was

Table 9: Results for Robustness

Parameter Used for Sample Analysis	Peak Area	Retention Time	Theoretical Plates	Tailing Factor
Actual Flow rate of 1.0 mL/min	1658242	2.312	6569	1.24
Less Flow rate of 0.9 mL/min	1854215	2.458	6865	1.35
More Flow rate of 1.1 mL/min	1758468	2.032	6254	1.32

SUMMARY AND CONCLUSION

The analytical method was developed by studying different parameters. First of all, maximum absorbance was found to be at 235nm and the peak purity was excellent. Injection volume was selected to be 10 µl which gave a good peak area. The column used for study was Symmetry ODS C₁₈ (4.6×250mm, 5 µm) because it was giving good peak. Ambient temperature was found to be suitable for the nature of drug solution. The flow rate was fixed at 1.0 ml/min because of good peak area and satisfactory retention time. Mobile phase is Methanol: Phosphate Buffer pH-3.6 in the ratio of 35:65 v/v was fixed due to good symmetrical peak. So this mobile phase was used for the proposed study. Methanol was selected because of maximum extraction sonication time was fixed to be 10 min at which all the drug particles were completely soluble and showed good recovery. Run time was selected to be 8 min because analyze gave peak around 2.276 and also to reduce the total run time. The percent recovery was found to be 98.0-102 was linear and

precise over the same range. Both system and method precision were found to be accurate and well within range. The analytical method was found linearity over the range of 6-14 ppm of the Zafirlukast target concentration. The analytical passed both robustness and ruggedness tests. On both cases, relative standard deviation was well satisfactory.

BIBLIOGRAPHY

1. <https://go.drugbank.com/drugs/DB00549>
2. <https://pubchem.ncbi.nlm.nih.gov/compound/Zafirlukast>
3. <https://en.wikipedia.org/wiki/Zafirlukast>
4. Andrea Weston and Phyllisr. Brown, HPLC Principle and Practice, 1st edition, Academic press, (1997), PP 24-37.
5. Yuri Kazakevich and Rosario Lobrutto, HPLC for Pharmaceutical Scientists, 1st edition, Wiley Inter science A John Wiley & Sons, Inc., Publication, (2007), PP 15-23.
6. Dr. Kealey and P.J Haines, Analytical Chemistry, 1st edition, Bios Publisher, (2002), P1-7.

7. A. Braith Wait and F. J. Smith, *Chromatographic Methods*, 5th edition, Kluwer Academic Publisher, (1996), PP 1-2.
8. Chromatography, (online).
URL: <http://en.wikipedia.org/wiki/Chromatography>.
9. Meyer V.R. *Practical High-Performance Liquid Chromatography*, 4th Ed. England, John Wiley & Sons Ltd, (2004), PP 7-8.
10. Sahajwalla CG *a new drug development*, Vol 141, Marcel Dekker Inc., New York, (2004), PP 421–426.
11. Introduction to Column. (Online), URL: http://amitpatel745.topcities.com/index_files/study/column_care.pdf
12. Detectors used in HPLC (online)
URL: http://wiki.answers.com/Q/What_detectors_are_used_in_HPLC
13. Detectors (online),
URL: http://hplc.chem.shu.edu/NEW/HPLC_Book/Detectors/det_uvda.html
14. Detectors (online),
URL: http://www.dionex.com/enus/webdocs/64842-31644-02_PDA-100.pdf
15. Detectors (online),
URL: <http://www.ncbi.nlm.nih.gov/pubmed/8867705>
16. Detectors (online),
URL: <http://www.chem.agilent.com/Library/applications/59643559.pdf>
17. Detectors (online),
URL: <http://hplc.chem.shu.edu/new/hplcbook/detect or>
18. Draft ICH Guidelines on Validation of Analytical Procedures Definitions and terminology. Federal Register, vol 60. IFPMA, Switzerland, (1995), PP 1126.
19. Code Q2B, Validation of Analytical Procedures; Methodology. ICH Harmonized Tripartite Guidelines, Geneva, Switzerland, (1996), PP 1- 8.
20. Introduction to analytical method validation (online), available from:
URL: <http://www.standardbase.hu/tech/HPLC%20validation%20PE.pdf>.
21. Data elements required for assay validation, (online) available from:
URL: <http://www.labcompliance.com/tutorial/methods/default.aspx>.
22. Snyder LR *practical HPLC method development*, 2nd edition. John Wiley and sons, New York, (1997), PP 180-182.
23. Skoog D A, West D M, Holler FJ: *Introduction of analytical chemistry*. Sounder college of publishing, Harcourt Brace college publishers. (1994), PP 1-5.
24. Sharma B K, *Instrumental method of chemical analysis* Meerut. (1999), PP 175-203.
25. Breaux J and Jones K: Understanding and implementing efficient analytical method development and validation. *Journal of Pharmaceutical Technology* (2003), 5, PP 110-114.
26. Willard, H. y. Merritt L.L, Dean J.A and Settle F.A “*Instrumental Methods of Analysis*” 7th edition CBS publisher and distributors, New Delhi, (1991), PP 436-439.
27. ICH Q2A, “Validation of Analytical Methods, Definitions and Terminology”, ICH Harmonized tripartite guideline, (1999).
28. Thilak Kumar Thiyagarajan, Jamal Abdul Nasser Abdul Hakeem, Vijayakumar Baksam, *Journal of Chromatographic Science*, Volume 50, Issue 10, November/December 2012, Pages 945–952.
<https://doi.org/10.1093/chromsci/bms095>.
29. B. Roopa Rani*, Dr. Ch. M. M. Pradada Rao, D. Dhachinamoorthi, *Analytical Method Development and Validation of Zafirlukast in Formulation by RP-HPLC*, *World Journal of Pharmaceutical and Medical Research*, wjpmr, 2018,4(4), 181 -187.
30. R. Ficarra, P. Ficarra, Silvana Tommasini, S. Melardi, Maria Luisa Calabrò, S. Furlanetto, Mohammad Semreen, Validation of a LC method for the analysis of Zafirlukast in pharmaceutical formulation, September 2000, *Journal of Pharmaceutical and Biomedical Analysis*, 23(1): 169-74, DOI:10.1016/S0731-7085(00)00266-1.
31. R. M. Singh, P. K. Saini, S. C. Mathur, G. N. Singh, and B. Lal1, Development and Validation of a RP-HPLC Method for Estimation of Montelukast Sodium in Bulk and in Tablet Dosage Form, *Indian J Pharm Sci.* 2010 Mar-Apr; 72(2): 235–237, Doi: 10.4103/0250-474X.65023.